Advertisement
Advertisement

ERAS

ERAS logo

Erasca, Inc. Common Stock

10.12
USD
Sponsored
-0.28
-2.69%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

10.16

+0.04
+0.44%

ERAS Earnings Reports

Positive Surprise Ratio

ERAS beat 11 of 19 last estimates.

58%

Next Report

Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.10
Implied change from Q1 26 (Revenue/ EPS)
--
/
--
Implied change from Q2 25 (Revenue/ EPS)
--
/
-16.67%

Erasca, Inc. Common Stock earnings per share and revenue

On May 07, 2026, ERAS reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.21 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.69% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
logo
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
logo
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
logo
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
logo
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
logo
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
logo
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
logo
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
FAQ
For Q1 2026, Erasca, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
The stock price moved down -2.69%, changed from $10.40 before the earnings release to $10.12 the day after.
The next earning report is scheduled for Aug 10, 2026.
Based on 7 analysts, Erasca, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement